The Global Health Innovative Technology Fund (GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), 16 pharmaceutical and diagnostics companies (Astellas, Chugai, Eisai, Daiichi Sankyo, Fujifilm, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck Group, Mitsubishi Tanabe, Nipro, Otsuka, Shionogi, Sumitomo Dainippon, Sysmex and Takeda), the Bill & Melinda Gates Foundation, the Wellcome Trust and United Nations Development Programme. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. Bill Gates has noted that "GHIT draws on the immense innovation capacity of Japan’s pharmaceutical companies, universities and research institutions to accelerate the creation of new vaccines, drugs and diagnostic tools for global health." Margaret Chan, former Director-General of the World Health Organization, said: "The GHIT Fund has stepped in to provide that incentive in a pioneering model of partnership that brings Japanese innovation, investment and leadership to the global fight against infectious disease." More information...
According to PR-model, ghitfund.org is ranked 799,158th in multilingual Wikipedia, in particular this website is ranked 76,160th in Japanese Wikipedia.
The website is placed before lecheneauxpiedsbleus.com and after icbff2013.com in the BestRef global ranking of the most important sources of Wikipedia.
